中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

476 records (took 0.036 seconds)

    SELECTIVE FACTOR Xa INHIBITORS
    51.
    发明申请
    SELECTIVE FACTOR Xa INHIBITORS 审中-公开
    选择性因子Xa抑制剂

    公开(公告)号：WO1998016547A1

    公开(公告)日：1998-04-23

    申请号：PCT/US1997018312

    申请日：1997-10-10

    Applicant: COR THERAPEUTICS, INC.

    Inventor： COR THERAPEUTICS, INC. ,  ZHU, Bing-Yan ,  SCARBOROUGH, Robert, M.

    IPC: C07K05/06

    CPC classification number: C07K5/06191 ,  A61K38/00

    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

    Abstract translation: 本发明涉及显示抗哺乳动物因子Xa活性的新化合物，其盐及其组合物。 这些化合物在体外或体内用于凝血障碍的预防性或治疗性治疗。

    SELECTIVE FACTOR Xa INHIBITORS
    52.
    发明申请
    SELECTIVE FACTOR Xa INHIBITORS 审中-公开
    选择性因子Xa抑制剂

    公开(公告)号：WO1998016525A1

    公开(公告)日：1998-04-23

    申请号：PCT/US1997018647

    申请日：1997-10-10

    Applicant: COR THERAPEUTICS, INC.

    Inventor： COR THERAPEUTICS, INC. ,  ZHU, Bing-Yan ,  SCARBOROUGH, Robert, M.

    IPC: C07D417/14

    CPC classification number: C07D417/12 ,  C07F5/025

    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

    Abstract translation: 本发明涉及具有抗哺乳动物因子Xa活性的新化合物及其盐和相关组合物。 这些化合物在体外或体内可用于预防或治疗凝血病症。

    AGENTS AFFECTING THROMBOSIS HEMOSTASIS
    55.
    发明申请
    AGENTS AFFECTING THROMBOSIS HEMOSTASIS 审中-公开
    影响血栓形成的药剂

    公开(公告)号：WO1996000577A1

    公开(公告)日：1996-01-11

    申请号：PCT/US1995008368

    申请日：1995-06-28

    Applicant: COR THERAPEUTICS, INC.

    Inventor： COR THERAPEUTICS, INC. ,  WOLF, David, L. ,  SINHA, Uma

    IPC: A61K35/16

    CPC classification number: C12N9/6464 ,  A61K38/00 ,  C07K14/745 ,  C12N9/6432 ,  C12N9/647 ,  C12Y304/21006 ,  C12Y304/21069 ,  Y10S514/834 ,  Y10S530/83

    Abstract: Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

    Abstract translation: 瞬时失活的血液因子的类似物可用于治疗以血栓形成为特征的疾病。 此外，在血清中产生活性血因子但具有延长半衰期的活化血液因子的修饰形式可用于治疗血液病症。 血液因子的这些修饰形式可以是在体内缓慢脱酰基化的酰化形式。

    PLATELET GLYCOPROTEIN V GENE AND USES
    56.
    发明申请
    PLATELET GLYCOPROTEIN V GENE AND USES 审中-公开
    PLATELET GLYCOPROTEIN V基因和用途

    公开(公告)号：WO1995002054A2

    公开(公告)日：1995-01-19

    申请号：PCT/US1994007644

    申请日：1994-07-07

    Applicant: COR THERAPEUTICS, INC.

    Inventor： COR THERAPEUTICS, INC. ,  LANZA, François ,  PHILLIPS, David, R. ,  CAZENAVE, Jean-Pierre

    IPC: C12N15/12

    CPC classification number: C07K14/705 ,  A61K38/00

    Abstract: This invention relates to the glycoprotein v gene. Specifically, this invention discloses the sequence and structure of the glycoprotein v gene and the amino acid sequence of the glycoprotein v polypeptide. In addition, the evolutionary relationship of the glycoprotein v gene with other glycoproteins is described and several uses of the isolated glycoprotein v gene are shown.

    Abstract translation: 本发明涉及糖蛋白v基因。 具体地，本发明公开了糖蛋白v基因的序列和结构以及糖蛋白v多肽的氨基酸序列。 此外，描述了糖蛋白v基因与其他糖蛋白的进化关系，并显示了分离的糖蛋白v基因的几种用途。

    THROMBIN RECEPTOR ANTAGONISTS
    57.
    发明申请
    THROMBIN RECEPTOR ANTAGONISTS 审中-公开
    硫蛋白受体拮抗剂

    公开(公告)号：WO1994003479A1

    公开(公告)日：1994-02-17

    申请号：PCT/US1993006428

    申请日：1993-07-08

    Applicant: COR THERAPEUTICS, INC. ,  SCARBOROUGH, Robert, M.

    Inventor： COR THERAPEUTICS, INC.

    IPC: C07K05/00

    CPC classification number: C07K7/06 ,  A61K38/00 ,  C07K5/06078 ,  C07K5/1016 ,  C07K7/02

    Abstract: Peptide derivatives serving as thrombin receptor antagonists are disclosed, which bear specificity for the cellular thrombin receptor without interfering with the catalytic activities of thrombin. The derivatives generally have formula (I) in which R1 and R3 are amide linkages, N-alkylamide linkages, or isosteric replacements of such linkages; R2 is either a neutral amino acid side chain or a hydrophobic radical; R4 is hydrophobic radical; R5 is CO, CH2 or SO; X is either of formula (II) in which R6 and R7 are H, alkyl, cycloalkylalkyl, alkoxyalkyl, alkylthioalkyl or arylalkyl, and R8 is a hydrophobic radical, or a hydrophobic residue; Y is alkoxy, hydroxy, amino, alkylamino, dialkylamino, in which any of the alkyl groups may be substituted with a basic moiety; Z is an amino acid or peptide residue; and m is zero or one.

    Abstract translation: 公开了用作凝血酶受体拮抗剂的肽衍生物，其对细胞凝血酶受体具有特异性，而不干扰凝血酶的催化活性。 衍生物通常具有式（I），其中R 1和R 3是酰胺键，N-烷基酰胺键或这种键的等排取代基; R2是中性氨基酸侧链或疏水基团; R4是疏水基; R5是CO，CH2或SO; X为式（Ⅱ）中R6和R7为H，烷基，环烷基烷基，烷氧基烷基，烷硫基烷基或芳基烷基，R8为疏水基团或疏水残基; Y是烷氧基，羟基，氨基，烷基氨基，二烷基氨基，其中任何烷基可被碱部分取代; Z是氨基酸或肽残基; m为0或1。

Patent Agency Ranking